TRINETRA › Sectors › Healthcare
Alivus Life Sciences Limited (ALIVUS) — share price, P/E and fundamentals
Alivus Life Sciences Limited (NSE: ALIVUS) closed at ₹1,415.30 on 30 Oct 2026, +53.3% over one year, against a 52-week range of ₹819.00 – ₹1,499.00.
In the quarter ended 30 Sept 2026 (standalone, filed 29 Oct 2026) it reported revenue of ₹682 cr and net profit of ₹197 cr, a 28.9% net margin; revenue grew 16.0% and profit grew 50.4% year on year.
On four consecutive filed quarters its trailing P/E is 25.9; since 15 May 2025 its own P/E has ranged from 19.4 to 30.4 (median 23.8), and today's reading is higher than 77% of those 361 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 21.7%, ROCE 27.9%, debt-to-equity 0.00, Piotroski F-score 8 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 95% of 64 sector peers; PBT margin higher than 98% of 64 sector peers; ROE higher than 80% of 64 sector peers.
Key figures
| Last close | ₹1,415.30 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | +3.3% / +34.8% / +53.3% |
| 52-week low – high | ₹819.00 – ₹1,499.00 |
| Market capitalisation | ₹17,376 cr |
| Trailing P/E | 25.9 |
| Price / book | 4.78 |
| EV / EBITDA | 17.8 |
| Earnings yield | 3.9% |
| TTM EPS | ₹54.55 |
| TTM net profit | ₹670 cr |
| Quarter revenue | ₹682 cr |
| Quarter net profit | ₹197 cr |
| Net margin | 28.9% |
| Revenue growth (YoY) | +16.0% |
| Profit growth (YoY) | +50.4% |
| Return on equity | 21.7% |
| ROCE | 27.9% |
| Debt / equity | 0.00 |
| Current ratio | 5.08 |
| Free cash flow | ₹270 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹11.4 cr |
Against Healthcare peers
| Metric | ALIVUS | Peer median | Percentile |
|---|---|---|---|
| Net margin | 28.85 | 12.89 | 95 |
| PBT margin | 38.41 | 17.68 | 98 |
| ROE | 21.67 | 13.87 | 80 |
| ROCE | 27.87 | 17.26 | 83 |
| Debt / equity | 0.00 | 0.11 | 12 |
| FCF margin | 20.43 | -0.87 | 87 |
| Cash conversion | 1.29 | 1.25 | 52 |
| Trailing P/E | 25.94 | 43.26 | 14 |
Questions
What is the P/E ratio of Alivus Life Sciences Limited?
Alivus Life Sciences Limited's trailing P/E is 25.9, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 15 May 2025 its P/E has ranged 19.4–30.4.
What were Alivus Life Sciences Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Alivus Life Sciences Limited reported revenue of ₹682 cr and net profit of ₹197 cr (standalone), filed with the exchange on 29 Oct 2026.
What is Alivus Life Sciences Limited's ROE?
Return on equity is 21.7% based on the balance sheet dated 30 Sept 2026.
Does Alivus Life Sciences Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 30 Sept 2026.
What is ALIVUS's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, ALIVUS traded between ₹819.00 and ₹1,499.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: standalone SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.